Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “relacorilant” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 14
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 14 pipeline programs matching "relacorilant" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

14 results for “relacorilant” Back to intelligence hub

Search results

  1. Relacorilant

    CORCEPT THERAPEUTICS INC

    Hypercortisolism

    phase 3 small molecule completed

    1 trial
  2. Relacorilant, 100 mg and 25 mg

    CORCEPT THERAPEUTICS INC

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule terminated

    1 trial
  3. relacorilant

    CORCEPT THERAPEUTICS INC

    Cushing Syndrome

    phase 3 small molecule active

    2 trials
  4. Relacorilant

    CORCEPT THERAPEUTICS INC

    Recurrent Ovarian Cancer

    phase 2 small molecule completed

    1 trial
  5. Relacorilant 150 mg once daily (QD)

    CORCEPT THERAPEUTICS INC

    Adenocarcinoma

    phase 2 small molecule active

    1 trial
  6. Relacorilant 150 mg once daily (QD)

    CORCEPT THERAPEUTICS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial
  7. Relacorilant with nab-paclitaxel

    CORCEPT THERAPEUTICS INC

    Solid Tumors

    phase 2 small molecule completed

    1 trial
  8. Relacorilant

    CORCEPT THERAPEUTICS INC

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial
  9. Relacorilant

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial
  10. Relacorilant

    CORCEPT THERAPEUTICS INC

    Adrenocortical Carcinoma

    phase 1 small molecule completed

    1 trial
  11. Relacorilant (3x100 mg softgel capsules)

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial
  12. Relacorilant 350mg

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial
  13. Relacorilant Fasted

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial
  14. Relacorilant under fasted conditions

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.